DailyMed Label Places Homeopathic Antifungal Foot and Body Product Under Regulatory Scrutiny
DailyMed’s latest label entry for ANTI FUNGAL FOOT AND BODY pairs sepia officinalis juice with tea tree oil and classifies the product as a human OTC drug with an unapproved homeopathic marketing status. The label is explicit: this is not an FDA-evaluated therapy for safety or efficacy, and no scientific evidence is cited in the labeling itself to support homeopathy as an effective treatment approach.
The product is positioned for superficial fungal disease on the skin, including jock itch, ringworm, athlete’s foot, and tinea versicolor. Its advertised symptom relief covers itching, scaling, cracking, burning, and irritation. Those are common complaints in dermatologic fungal infections, but the therapeutic claims here rest on a label that stands outside the usual evidentiary pathway used for approved antifungal medications.
A topical product with antifungal marketing language can look interchangeable with standard therapy at first glance. It is not.
What the Label Says the Product Contains and What It Claims to Treat
The active ingredients listed are SEPIA OFFICINALIS JUICE at 12 hp_X in 1 mL and tea tree oil at 0.04 g in 1 mL. The inactive ingredient list includes lauramidopropyl betaine, panthenol, phospholipid EFA, purified water, sodium chloride, sodium C14-16 olefin sulfonate, and tea tree oil. The package is identified as NDC 83004-011-01, a 500 mL pump bottle marketed by Rida LLC.
The label directs use for common dermatophyte and yeast-associated rashes: jock itch, ringworm, athlete’s foot, and tinea versicolor. In clinical terms, those conditions often involve hot, moist, occluded skin surfaces where fungal proliferation is aided by friction and maceration. The same ecological conditions explain why the feet, groin, trunk, and intertriginous zones are frequent targets for recurrence when hygiene, footwear, or skin barrier management is poor.
One practical detail stands out immediately: the product is not effective on scalp or nails.
That limitation matters because fungal disease of the nails and scalp usually requires a different diagnostic approach, longer treatment courses, and in many cases systemic therapy rather than a surface wash or topical rinse. Patients with thickened dystrophic nails or inflammatory scalp scaling could mistake this product for a broader antifungal solution, yet the label confines its use to skin disease and explicitly excludes those sites.
Use Instructions Emphasize Surface Hygiene, Not Proven Antifungal Potency
DailyMed instructs users to clean the affected area with an anti-fungal wash and warm water, rinse, and dry thoroughly before application. The product is then left on for 1–2 minutes before rinsing and drying, with twice-daily use in the morning and night, or as directed by a doctor. Treatment duration is listed as 2 weeks for jock itch and 4 weeks for ringworm, athlete’s foot, and tinea versicolor.
Those directions resemble a supportive skin-care ritual as much as a pharmacologic intervention. Drying the skin, reducing occlusion, and changing socks and shoes frequently can interrupt the moist environment fungi need to persist. For athlete’s foot, the label specifically instructs attention to the spaces between the toes, along with well-fitting ventilated shoes and daily changes of shoes and socks. In everyday practice, those measures can reduce reinoculation and maceration even when the medication effect itself is uncertain.
The product is intended for use by normally healthy adults only, and persons under 18 years of age or those with highly sensitive or allergic skin should use only as directed by a doctor. Children should be supervised in use of the product. Those restrictions imply caution around skin barrier fragility and the higher likelihood of irritation in younger users or patients with sensitive skin phenotypes.
Safety Warnings Focus on Irritation, Eye Exposure, and Delayed Response
The warning language is straightforward: for external use only. Avoid the eyes, rinse thoroughly if contact occurs, and stop use if irritation develops. Users are also told to seek medical advice if there is no improvement within 2 weeks, or within 4 weeks for ringworm, athlete’s foot, and tinea versicolor.
That instruction set is clinically important because persistent rash after a topical antifungal claim can represent several different problems. The diagnosis may be wrong. The rash may be inflammatory rather than fungal. A bacterial superinfection, irritant dermatitis, psoriasis, eczema, or a resistant fungal infection can also masquerade as the original complaint. When a product carries a homeopathic label and delayed improvement is built into the warning language, clinicians need to treat lack of response as a prompt to reassess the diagnosis rather than to simply continue the same regimen.
Swallowed product requires immediate medical attention or contact with a Poison Control Center. That warning is routine for topical agents but still relevant in households with small children, where liquid preparations and pump bottles can be accessible.
Regulatory Status Defines the Real Clinical Boundary
The label identifies this as a human OTC drug with unapproved homeopathic marketing status. DailyMed also states that the product has not been evaluated by the Food and Drug Administration for safety or efficacy and that FDA is not aware of scientific evidence supporting homeopathy as effective. That regulatory framing does not address whether individual ingredients may have traditional or anecdotal use; it does define what the label cannot claim in evidentiary terms.
For clinicians and pharmacists, the key issue is not the packaging language alone. It is whether a patient with fungal symptoms may delay proven treatment while relying on a product that lacks FDA-evaluated efficacy. Superficial mycoses are often manageable, but untreated or undertreated disease can spread across skin surfaces, recur after partial suppression, or trigger ongoing discomfort that drives unnecessary self-treatment.
The updated label date is October 16, 2026, and the version history shows prior label versions in 2024 and 2025, with the current version marked as version 3. The product’s continued presence in DailyMed keeps the regulatory record visible, but the label itself remains anchored to an unapproved homeopathic status and to a narrow, surface-level use case. For patients, that leaves a simple clinical question: if a rash does not improve on schedule, the label itself points back toward formal evaluation rather than prolonged self-management.